Sanofi-Aventis will buy Shantha Biotechnics, a Hyderabad, India-based vaccine company. According to an SA statement, “Sanofi Pasteur, the vaccines division of the Sanofi-Aventis Group, will support Shantha’s ongoing development as a platform to address the need for high quality affordable vaccination in international markets.” The transaction values Shantha at $780 million; the unit’s Shantha’s sales this fiscal year are projected to be $90 million. Shantha, founded i...